TL;DR
Scientists are revisiting glycol vapors—an old disinfectant technology—to assess their potential in preventing airborne disease transmission. New research aims to confirm safety and efficacy for pandemic preparedness.
Recent scientific efforts are focusing on the potential use of glycol vapors to inactivate airborne viruses and reduce the spread of respiratory diseases, including future pandemics. This renewed interest follows decades of preliminary research and recent government-funded studies aiming to evaluate their safety and effectiveness in real-world settings.
Glycol vapors, including propylene glycol, dipropylene glycol, and triethylene glycol, are known to rapidly inactivate viruses, bacteria, and fungi when vaporized into indoor air. Historically, studies from the 1940s showed significant reductions in respiratory illnesses in hospital wards treated with glycol vapors, with some reports indicating up to 96% fewer colds and 90% fewer cases of related infections. Despite this, interest waned with the advent of antibiotics and modern disinfection methods. During the COVID-19 pandemic, the EPA granted emergency approval in six states for glycol-based disinfectants, but scientific research remained limited, and public health agencies expressed skepticism about their use in occupied spaces. Currently, a $4.5 million research initiative, GlycolISER, funded by Blueprint Biosecurity, aims to scientifically evaluate the safety, efficacy, and practical deployment of glycol vapors in various environments, with initial findings expected by 2027.
Why It Matters
If proven safe and effective, glycol vapors could become a cost-effective, scalable tool to reduce airborne transmission of viruses like influenza, SARS-CoV-2, and future pathogens. This approach could enhance pandemic preparedness, especially in indoor settings such as hospitals, schools, and public transportation, potentially saving lives and reducing economic impacts of outbreaks.
propylene glycol vapor disinfectant
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
The concept of using glycol vapors for infection control dates back to the 1940s, with early studies demonstrating their disinfectant properties. Interest declined after antibiotics became widespread, but recent pandemics have reignited research efforts. The COVID-19 crisis highlighted gaps in airborne pathogen mitigation, prompting regulatory agencies to explore alternative methods. The current research builds on historical data and aims to address previous limitations by rigorously evaluating safety and efficacy in modern settings.
“This research shows where the potential could be for glycol vapors to be part of our pandemic defense toolkit.”
— Jacob Swett, Blueprint Biosecurity
“Glycol vapors are particularly effective against enveloped viruses like SARS-CoV-2, influenza, and Ebola.”
— Curtis Donskey, Cleveland VA Medical Center
“Robust evaluation of glycol vapors is essential to understand their potential and limitations in reducing airborne disease transmission.”
— Brian Renda, Blueprint Biosecurity
industrial glycol vapor air purifier
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
While preliminary data and historical studies are promising, it remains unclear how well glycol vapors will perform in diverse real-world environments, their long-term safety for sensitive populations, and the optimal deployment methods. Further research is needed to address these questions.
hospital-grade glycol vapor sterilizer
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
The GlycolISER program will conduct multidisciplinary studies over the next few years, focusing on pathogen inactivation efficacy, safety profiles, and deployment strategies. Initial results are anticipated by early to mid-2027, which will inform potential regulatory approvals and practical applications.
air disinfection system with glycol vapors
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Are glycol vapors safe for indoor use?
Current research aims to establish safety profiles, especially for sensitive populations. Historically, glycol vapors have been used in various settings, but comprehensive safety assessments are ongoing to confirm their suitability for widespread indoor deployment.
How effective are glycol vapors against airborne viruses?
Historical studies suggest significant inactivation of viruses like influenza and coronaviruses, but modern, controlled research is needed to confirm their effectiveness in current indoor environments.
Could glycol vapors be used in everyday spaces like homes and offices?
If proven safe and effective, glycol vapors could be integrated into HVAC systems or other air management solutions, but regulatory approval and further testing are required before widespread use.
What are the next steps in this research?
The GlycolISER program will conduct laboratory and field studies over the next two years to evaluate efficacy, safety, and deployment methods, with initial findings expected by 2027.
